Log in to search using one of your social media accounts:

 

Characteristics and Outcomes of Malignancy-Associated Hemophagocytic Lymphohistiocytosis (M-HLH) in Adult Patients: A Single-Center Experience
HLH is a systemic condition characterized by inflammatory storm and immune-mediated organ damage. Adult M-HLH is challenging and lethal due to under recognition and diverse presentations. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - October 1, 2017 Category: Hematology Authors: Rita Assi, Prajwal Boddu, Tapan Kadia, Guillermo Garcia-Manero, Farhad Ravandi, Elias Jabbour, Koichi Takahashi, Marina Konopleva, Abdallah Abou Zahr, Courtney DiNardo, Gautam Borthakur, Nitin Jain, Naveen Pemmaraju, Jing Ning, Sherry Pierce, William Wier Tags: Infection, Inflammation and Cancer Source Type: research

Intercorrelation of Expression of CD56, CD117, CD33, CD20 Antigens with Survival Rates in Patients with Multiple Myeloma in Gomel Region in Belarus
The detection of immunophenotype of plasma cells is very important for diagnosis of multiple myeloma. Mechanism of appearing of different antigens on the surface of malignant plasma cells and their correlation with overall survival isn't sufficiently studied. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - October 1, 2017 Category: Hematology Authors: Z. Kozich, V. Martinkov, Z. Pugacheva, L. Smirnova Tags: Multiple Myeloma Source Type: research

Molecular Pathophysiology of Myeloma and Clinical Applications
Therapies targeting multiple myeloma (MM) in its bone marrow (BM) microenvironment including proteasome inhibitors (PIs), immunomodulatory drugs (IMiDs), histone deacetylase (HDAC) inhibitors, and monoclonal antibodies (MoAbs), prolong survival 3 to 4 fold. Novel therapies target ubiquitin proteasome receptor upstream of the proteasome to overcome PI resistance. HDAC6 inhibitors block aggresomal protein degradation and synergize with PIs. IMiDs bind and activate cereblon ubiquitin 3 ligase in MM, with degradation of IZF1/3 and downregulation of Myc and IRF4. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - October 1, 2017 Category: Hematology Authors: Kenneth Anderson Source Type: research

Elevated Peripheral Blood (4-9%) and Bone Marrow Blasts (5-9%) are Associated with Poor Prognosis in Patients with Primary Myelofibrosis as Well as Post-Essential Thrombocythemia and Post-Polycythemia Vera Myelofibrosis
Patients with accelerated phase (AP) myelofibrosis (MF;>10% blasts in bone marrow [BM] or peripheral blood [PB]) have shorter overall survival (OS) than those in the chronic phase ( (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - October 1, 2017 Category: Hematology Authors: Lucia Masarova, Hagop M. Kantarjian, Srdan Verstovsek Tags: Myeloproliferative Neoplasms Source Type: research

Editorial Board/Masthead
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - October 1, 2017 Category: Hematology Source Type: research

Table of Contents
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - October 1, 2017 Category: Hematology Source Type: research

Organizing Committees
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - October 1, 2017 Category: Hematology Source Type: research

Message from the Chairmen
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - October 1, 2017 Category: Hematology Source Type: research

Editorial Board
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - October 1, 2017 Category: Hematology Source Type: research

Table of Contents
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - October 1, 2017 Category: Hematology Source Type: research

SOHO State of the Art Update and Next Questions: Biology and Treatment of Myelodysplastic Syndromes
Myelodysplastic syndromes (MDS) are a heterogeneous group of myeloid neoplasms characterized by clonal hematopoiesis leading to bone marrow dysplasia and cytopenias. Recently, significant advancements have been made in understanding the pathogenic mechanisms of this disease. In particular, how a wide array of somatic mutations can induce a common clinical phenotype has been investigated. Specifically, activation of innate immune signaling (i.e. myeloid derived suppressor cells) and the NLRP3 inflammasome in hematopoietic stem/progenitor cells play a central role in the biology of MDS, leading to pyroptotic cell death and c...
Source: Clinical Lymphoma, Myeloma and Leukemia - September 25, 2017 Category: Hematology Authors: David A. Sallman, Tiffany N. Tanaka, Alan List, Rafael Bejar Tags: SOHO State of the Art Updates and Next Questions Source Type: research

Clinical practice guidelines for diagnosis and treatment of chronic lymphocytic leukemia (CLL) in the Netherlands
In recent years, considerable progress has been made in treatment of patients with chronic lymphocytic leukaemia (CLL) and new potent drugs have become available.Therefore, the CLL working party of the Dutch/ Belgium Haemato-Oncology Foundation for Adults in the Netherlands (HOVON) framework revised the Dutch guidelines based on new studies and expert opinion of members of the working group. Not only efficacy, but also quality of life and socio-economic impact were taken into account in the formulation of the recommendations. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 25, 2017 Category: Hematology Authors: S. Kersting, S.I.M. Neppelenbroek, H.P.J. Visser, M v Gelder, M.D. Levin, R. Mous, E.F.M. Posthuma, H.M. van der Straaten, A.P. Kater Source Type: research

Outcomes of patients with relapsed core binding factor-positive acute myeloid leukemia
Patients with CBF-AML who relapse have suboptimal outcomes. We retrospectively analyzed 92 CBF-AML patients at first relapse to identify factors associated with clinical outcome. Age, high white cell count, high bone marrow blast percentage and t(8;21) cytogenetic group were associated with worse prognosis. Our findings suggest that consideration of these factors, especially t(8;21) cytogenetics, can improve prognostic stratification of patients. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 25, 2017 Category: Hematology Authors: Maliha Khan, Jorge Cortes, Wei Qiao, Mohanad A. Alzubaidi, Sherry A. Pierce, Farhad Ravandi, Hagop M. Kantarjian, Gautam Borthakur Source Type: research

SOHO State of the Art Update and Next Questions: Biology and Treatment of MDS
Myelodysplastic Syndromes (MDS) are a heterogeneous group of myeloid neoplasms characterized by clonal hematopoiesis leading to bone marrow dysplasia and cytopenias. Recently, significant advancements have been made in understanding the pathogenic mechanisms of this disease. In particular, how a wide array of somatic mutations can induce a common clinical phenotype has been investigated. Specifically, activation of innate immune signaling (i.e. myeloid derived suppressor cells) and the NLRP3 inflammasome in hematopoietic stem/progenitor cells play a central role in the biology of MDS leading to pyroptotic cell death and cl...
Source: Clinical Lymphoma, Myeloma and Leukemia - September 25, 2017 Category: Hematology Authors: David A. Sallman, Tiffany N. Tanaka, Alan List, Rafael Bejar Source Type: research

Extranodal Marginal Zone Lymphoma of the Central Nervous System
We present a review of the literature and describe its presentation, differential diagnosis, treatment options, and outcomes. Systematic search of PubMed, Medline, and Embase databases via the Ovid engine for primary articles and case reports yielded 37 unduplicated peer-reviewed articles of CNS EMZBL. We identified 69 cases in these articles and 1 unreported case at our institution, which were included for this review's analysis. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 22, 2017 Category: Hematology Authors: Adanma Ayanambakkam, Sami Ibrahimi, Khalid Bilal, Mohamad A. Cherry Tags: Review Source Type: research

The Role of Radiation in All Stages of Nodular Lymphocytic Predominant Hodgkin Lymphoma
We assessed the role of radiotherapy (RT) in nodular lymphocytic Hodgkin lymphoma (NLPHL), particularly among patients with advanced stage disease, and B symptoms. We found that among NLPHL patients, RT had a potential role in advanced-stage disease and those with B symptoms, suggesting further exploratory studies. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 22, 2017 Category: Hematology Authors: Bismarck Odei, Dustin Boothe, Jonathan Frandsen, Matthew M. Poppe, David K. Gaffney Source Type: research

Results of upfront therapy for marginal zone lymphoma
Marginal zone lymphomas (MZL) represent a group of indolent lymphomas that originates from the marginal zone of lymphoid tissue. [1-3] The World Health Organization classifies these indolent lymphomas into three distinct types based on their site of origin: extranodal mucosa-associated lymphoid tissue (MALT) MZL, nodal MZL (NMZL) and the splenic MZL (SMZL). Even though these entities share common features, they also display clinical, molecular and biological heterogeneity depending on the organ where they originate from. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 22, 2017 Category: Hematology Authors: Jos é L. Ortega, Fernando Cabanillas, Noridza Rivera, Maribel Tirado-Gomez, Deana Hallman, Wandaly I. Pardo, Margarita Bruno Source Type: research

Extra-Nodal Marginal Zone Lymphoma Of The Central Nervous System
We present a review of the literature and describe the presentation, differential diagnosis, treatment options and outcomes of CNS EMZBL. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 22, 2017 Category: Hematology Authors: Adanma Ayanambakkam, Sami Ibrahimi, Khalid Bilal, Mohamad A. Cherry Source Type: research

A Comparison of Clofarabine-based (GCLAC) and Cladribine-based (CLAG) Salvage Chemotherapy for Relapsed/Refractory AML
Salvage regimens for patients with relapsed/refractory acute myeloid leukemia (rrAML) lack comparative data for superiority. Thus, we conducted a retrospective analysis of clofarabine-based (GCLAC; filgrastim, clofarabine, cytarabine) versus cladribine-based (CLAG; filgrastim, cladribine, cytarabine) regimens in rrAML. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 22, 2017 Category: Hematology Authors: Benyam Muluneh, Kaitlyn Buhlinger, Allison M. Deal, Joshua F. Zeidner, Matthew C. Foster, Katarzyna Joanna Jamieson, Jill Bates, Hendrik W. Van Deventer Source Type: research

Consolidative Radiotherapy After Autologous Stem Cell Transplantation for Relapsed or Refractory Diffuse Large B-cell Lymphoma
Patients with relapsed or refractory diffuse large B-cell lymphoma undergoing autologous bone marrow transplantation benefited from consolidative involved-field radiotherapy (IFRT). All patients who underwent consolidative IFRT had improved locoregional control. Additionally, patients with enlarged lymphadenopathy had an improved locoregional control, disease-free survival, and overall survival at the 2-year evaluation. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 19, 2017 Category: Hematology Authors: Brendan G. Coutu, Christopher T. Wilke, Jianling Yuan, Qing Cao, Matthew R. Vernon, Chung Lee, Veronika Bachanova, Kathryn E. Dusenbery Tags: Original Study Source Type: research

Cellular Proliferation by Multiplex Immunohistochemistry Identifies High-Risk Multiple Myeloma in Newly Diagnosed, Treatment-Naive Patients
The plasma cell labeling index (PCLI) prognosticates survival in multiple myeloma (MM) yet is underutilized as a result of its technical difficulty. We retrospectively evaluated multiplex immunohistochemistry (mIHC) in 151 newly diagnosed patients as a clinically feasible alternative to PCLI. The mIHC correlated with PCLI results and was predictive of overall survival for MM. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 19, 2017 Category: Hematology Authors: Scott Ely, Peter Forsberg, Ihsane Ouansafi, Adriana Rossi, Alvin Modin, Roger Pearse, Karen Pekle, Arthur Perry, Morton Coleman, David Jayabalan, Maurizio Di Liberto, Selina Chen-Kiang, Ruben Niesvizky, Tomer M. Mark Tags: Original Study Source Type: research

Treatment Patterns and Outcomes in Early-stage Hodgkin Lymphoma in the Elderly: A National Cancer Database Analysis
Early-stage Hodgkin lymphoma is a highly curable malignancy. However, the outcomes for elderly patients have remained suboptimal. We conducted a retrospective study using the National Cancer Database to assess the therapies used for elderly patients with early-stage Hodgkin lymphoma from 2004 to 2012. Our results showed improved survival with combined chemotherapy and radiation therapy. However, the usage of the latter remains suboptimal. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 19, 2017 Category: Hematology Authors: Gaurav Goyal, Edward B. Maldonado, Tiffany J. Fan, Arun Kanmanthareddy, Peter T. Silberstein, Ronald S. Go, James O. Armitage Tags: Original Study Source Type: research

Consolidative radiotherapy following autologous stem cell transplant for relapsed or refractory diffuse large B-cell lymphoma.
To evaluate the role of consolidative radiotherapy in patients undergoing high dose chemotherapy and autologous stem cell transplant for relapsed or refractory diffuse large B-cell lymphoma (DLBCL). (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 19, 2017 Category: Hematology Authors: Brendan G. Coutu, Christopher T. Wilke, Jianling Yuan, Qing Cao, Matthew R. Vernon, Chung Lee, Veronika Bachanova, Kathryn E. Dusenbery Source Type: research

The Epidemiology and Clinical Associations of Stroke in Patients with Acute Myeloid Leukemia: A review of 10,972 admissions from the 2012 National Inpatient Sample
Acute leukemia predisposes patients toward the development of stroke. The latter, while devastating clinically, has been infrequently studied. Our study, using the 2012 National Inpatient Sample, found a 50-fold increase in the risk of stroke as compared to all inpatient admissions with a corresponding 5.5-fold increased risk of mortality. Significant risk factors for the development of stroke included UTI, hypernatremia and acute renal failure. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 19, 2017 Category: Hematology Authors: Christopher Del Prete, Taeha Kim, Frederick Lansigan, Joseph Shatzel, Harley Friedman Source Type: research

Cellular Proliferation by Multiplex Immunohistochemistry Identifies High Risk Multiple Myeloma in Newly Diagnosed, Treatment Na ïve Patients
The plasma cell labeling index (PCLI) prognosticates survival in multiple myeloma (MM) yet is underutilized due to technical difficulty. We retrospectively evaluated multiplex immunohistochemistry (mIHC) in 151 newly diagnosed patients as a clinically feasible alternative to PCLI. The mIHC correlated with PCLI results and was predictive of overall survival for MM. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 19, 2017 Category: Hematology Authors: Scott Ely, Peter Forsberg, Ihsane Ouansafi, Adriana Rossi, Alvin Modin, Roger Pearse, Karen Pekle, Arthur Perry, Morton Coleman, David Jayabalan, Maurizio Di Liberto, Selina Chen-Kiang, Ruben Niesvizky, Tomer M. Mark Source Type: research

Treatment Patterns and Outcomes in Early Stage Hodgkin Lymphoma in the Elderly: A National Cancer Database Analysis
Early stage Hodgkin lymphoma is a highly curable malignancy. However, outcomes for elderly patients remain suboptimal. We conducted a retrospective study using the National Cancer Database to assess therapies used among elderly patients with early stage Hodgkin lymphoma from 2004-2012. Our results show improved survival with combined chemotherapy and radiation therapy. However, the utilization of latter remains suboptimal. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 19, 2017 Category: Hematology Authors: Gaurav Goyal, Edward B. Maldonado, Tiffany J. Fan, Arun Kanmanthareddy, Peter T. Silberstein, Ronald S. Go, James O. Armitage Source Type: research

Impact of Synchronous Multiple Primary Malignant Tumors on Newly Diagnosed Hematologic Malignancies
The existence of synchronous multiple primary malignant tumors was not a significant risk factor for patients with newly diagnosed hematologic malignancies. It is important to provide adequate treatment to both hematologic malignancies and solid tumors appropriately. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 18, 2017 Category: Hematology Authors: Satoshi Nishiwaki, Shingo Okuno, Kotaro Suzuki, Shingo Kurahashi, Isamu Sugiura Tags: Original Study Source Type: research

Phase 2 Open-Label Study of Bortezomib, Cladribine, and Rituximab in Advanced, Newly Diagnosed, and Relapsed/Refractory Mantle-Cell and Indolent Lymphomas
The combination of bortezomib, cladribine, and rituximab is novel and effective in mantle-cell and indolent non-Hodgkin lymphomas. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 18, 2017 Category: Hematology Authors: Soham D. Puvvada, Jos é Guillen-Rodriguez, Abhijeet Kumar, Lora Inclán, Kara Heard, Xavier I. Rivera, Faiz Anwer, Jonathan H. Schatz, Daruka Mahadevan, Daniel O. Persky Tags: Original Study Source Type: research

A Phase II Study of CLAG Regimen Combined With Imatinib Mesylate for Relapsed or Refractory Acute Myeloid Leukemia
Given the lack of standard salvage chemotherapy regimen for relapsed or refractory (RR) acute myeloid leukemia (AML), a phase 2 clinical study of cladribine, cytarabine, G-CSF (CLAG) regimen in combination with imatinib mesylate (IM) in patients with RR-AML was conducted at the Moffitt Cancer Center. Between August 2009 and April 2011, 38 patients were treated and the overall response rate was 37% with a median overall survival of 11.1 month. Among responders, 8/14 patients proceeded to allogeneic hematopoietic cell transplant. Overall, CLAG plus IM was well tolerated, with encouraging signs of activity in patients with po...
Source: Clinical Lymphoma, Myeloma and Leukemia - September 18, 2017 Category: Hematology Authors: Abu-Sayeef Mirza, Jeffrey E. Lancet, Kendra Sweet, Eric Padron, Javier Pinilla-Ibarz, Lisa Nardelli, Christopher Cubitt, Alan F. List, Rami S. Komrokji Tags: Original Study Source Type: research

Stability of Spinal Bone Lesions in Patients With Multiple Myeloma After Radiotherapy —A Retrospective Analysis of 130 Cases
This retrospective analysis evaluated the response regarding bone density and stability of patients with osteolytic spinal bone lesions due to multiple myeloma after palliative radiotherapy. The rate of unstable lesions decreased from 51% to 24%, and the bone density showed a significant increase 6 months after radiotherapy. Palliative radiotherapy is an effective method resulting in a significant increase for local response and stability without severe RT-related toxicity. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 18, 2017 Category: Hematology Authors: Kristin Lang, Laila K önig, Thomas Bruckner, Robert Förster, Tanja Sprave, Ingmar Schlampp, Tilman Bostel, Stefan Welte, Nils H. Nicolay, Jürgen Debus, Harald Rief Tags: Original Study Source Type: research

Blood Transfusion Management and Transfusion-related Outcomes in Daratumumab-treated Patients With Relapsed or Refractory Multiple Myeloma
Daratumumab binds CD38 on red blood cells (RBCs), resulting in panagglutination in blood compatibility tests. RBC transfusions and transfusion-related adverse events from the phase 2 SIRIUS clinical trial were analyzed and an in-depth analysis from 2 clinical study sites is reported. RBC transfusion-related adverse events, including hemolysis, were not observed among daratumumab-treated patients, confirming that transfusions may be safely administered. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 18, 2017 Category: Hematology Authors: Ajai Chari, Suzanne Arinsburg, Sundar Jagannath, Toshihisa Satta, Ivey Treadwell, Donna Catamero, Gillian Morgan, Huaibao Feng, Clarissa Uhlar, Imran Khan, Parul Doshi, Saad Usmani Source Type: research

A Phase II, Open-Label Study of Bortezomib (Velcade ®), Cladribine, and Rituximab (VCR) in Advanced, Newly Diagnosed and Relapsed/Refractory Mantle Cell and Indolent Lymphomas
Bortezomib, Cladribine and Rituximab (VCR) is a novel and effective combination in mantle cell and indolent non-Hodgkin ’s lymphomas. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 18, 2017 Category: Hematology Authors: Soham D. Puvvada, Jose Guillen, Abhijeet Kumar, Lora Inclan, Kara Heard, Xavier I. Rivera, Faiz Anwer, Jonathan H. Schatz, Daruka Mahadevan, Daniel Persky Source Type: research

Stability of spinal bone lesions in patients with Multiple Myeloma after radiotherapy - a retrospective analysis of 130 cases
Objective of this retrospective analysis was the response evaluation regarding bone density and stability of patients with osteolytic spinal bone lesions due to multiple myeloma after palliative radiotherapy (RT). (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 18, 2017 Category: Hematology Authors: Kristin Lang, Laila K önig, Thomas Bruckner, Robert Förster, Tanja Sprave, Ingmar Schlampp, Tilman Bostel, Stefan Welte, Nils H. Nicolay, Jürgen Debus, Harald Rief Source Type: research

Outcomes of Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Following an Elective switch from Second Generation Tyrosine Kinase Inhibitor to Imatinib.
The second-generation TKIs (2G-TKIs) Dasatinib (DAS) and Nilotinib (NIL) yield faster responses in newly diagnosed chronic phase (CP) CML as compared to Imatinib (IM) however, long-term safety of these agents is a growing concern. We identified 20 patients with CP CML diagnosed between 08/2013 and 10/2016 who initiated 2G-TKIs and were then switched after optimal response at 3 months to IM. Second generation TKIs initiated were DAS (n=15), NIL (n=3), both sequentially due to intolerance (n=1). One other patient initiated therapy with Ponatinib on trial. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 18, 2017 Category: Hematology Authors: Vamsi K. Kota, Jee Hyun Kong, Martha L. Arellano, Fuad El Rassi, Manila Gaddh, Leonard T. Heffner, Elliott F. Winton, Anand P. Jillella, Morgan L. McLemore, H. Jean Khoury Source Type: research

A Phase II Study of CLAG Regimen in Combination with Imatinib Mesylate in Relapsed or Refractory Acute Myeloid Leukemia
There is no standard salvage chemotherapy regimen for relapsed or refractory (RR) Acute Myeloid Leukemia (AML). Preclinical data suggested synergy in vitro between cytarabine and Imatinib Mesylate (IM) on AML cell growth inhibition. After demonstrating safety and feasibility with a phase I study, we conducted a phase 2 clinical study of Cladribine, Cytarabine, G-CSF (CLAG) regimen in combination with IM in patients with RR-AML. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 18, 2017 Category: Hematology Authors: Abu-Sayeef Mirza, Jeffrey E. Lancet, Kendra Sweet, Eric Padron, Javier Pinilla-Ibarz, Lisa Nardelli, Christopher Cubitt, Alan F. List, Rami S. Komrokji Source Type: research

Impact of Synchronous Multiple Primary Malignant Tumors on Newly Diagnosed Hematological Malignancies
Existence of synchronous multiple primary malignant tumors was not a significant risk factor for patients with newly diagnosed hematological malignancies. It is important to provide adequate treatment for both hematological malignancies and solid tumors appropriately. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 18, 2017 Category: Hematology Authors: Satoshi Nishiwaki, Shingo Okuno, Kotaro Suzuki, Shingo Kurahashi, Isamu Sugiura Source Type: research

Editorial Board
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Source Type: research

Table of Contents
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Source Type: research

Retrospective Study of Adults With Acute Lymphoid Leukemia in Mexico City: First Report of the Working Group for Acute Leukemia (GTLA)
The prognosis of adult acute lymphoblastic leukemia (ALL) is dire, with a long-term survival of 40-50%. Several studies have reported a worse prognosis in Hispanics with ALL. There are no existing large multicenter series of ALL patients in Mexico that analyze survival. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Erick Crespo-Solis, Karla Espinosa-Bautista, Martha Alvarado-Ibarra, Etta Rozen-Fuller, Fernando Perez-Rocha, Chantal Nava-Gomez, Maricela Ortiz-Zepeda, Jose Luis Alvarez-Vera, Christian Omar Ramos-Pe ñafiel, Luis Antonio Meillon-Garcia, Sergio Rodriguez Source Type: research

KTE-C19 (anti-CD19 chimeric antigen receptor [CAR] T cell therapy) in pediatric and adolescent patients with relapsed/refractory acute lymphoblastic leukemia (R/R ALL): Preliminary Results of ZUMA-4
We present preliminary ZUMA-4 phase 1 results. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Daniel W. Lee, Alan Wayne, Van Huynh, Rupert Handgretinger, Rob Pieters, Gerard Michel, Andre Baruchel, Tobias Feuchtinger, Yves Bertrand, Michelle Hemiston, Patrick Brown, John Rossi, Yizhou Jiang, Lynn Navale, Shanna Stout, Jeff Aycock, Armen Mardiros, Source Type: research

Axi-cel, an Anti-CD19 Chimeric Antigen Receptor (CAR) T cell Therapy in Adult Patients (Pts) With Relapsed/Refractory Acute Lymphoblastic Leukemia (R/R ALL) in the ZUMA-3 Trial: Preliminary Results of Novel Safety Interventions
Outcomes in adult R/R ALL are poor. Promising results were observed with axi-cel (formerly KTE-C19) in B cell malignancies. Severe cytokine release syndrome (CRS) and neurologic events (NE) have been observed with anti-CD19 CAR T cell therapy in R/R ALL. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Bijal Shah, Wendy Stock, William Wierda, Max Topp, Marie Jos é Kersten, Roch Houot, Nicolas Boissel, Houston Holmes, Gary Schiller, Armen Mardiros, John Rossi, Yizhou Jiang, Tong Shen, Jeff Aycock, Shanna Stout, Jeff Wiezorek, Rajul Jain Source Type: research

Nelarabine in Adult Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia/Lymphoma(T-ALL/T-LBL): The Mayo Clinic Experience
First line treatment strategies for adults with T-ALL/T-LBL are suboptimal, with over 50% of patients relapsing. Long term survival in the relapsed and refractory setting is ∼10%. The goal of salvage therapy is to achieve a durable response as a bridge to stem cell transplant (HCT). Nelarabine, a purine nucleoside analog, has been used for salvage therapy with reasonable success. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Theodora Anagnostou, Mark R. Litzow, Michelle A. Elliott, Aref Al-Kali, Naseema Gangat, Kristen B. McCullough, Hassan Alkhateeb, Mrinal M. Patnaik Source Type: research

JAK2 V617F Acute Lymphoblastic Leukemia Secondary to Myeloproliferative Neoplasms (MPNs) or After Lenalidomide Exposure: Case Report and Review of the Literature
MPNs almost always transform to acute myeloid leukemia (AML). Delhommeau and colleagues studied the presence of the JAK2 V617F mutation in circulating B-, T- and natural killer (NK) cells of patients with PV and PMF, and detected it in B- and NK cells from approximately half their patients with PMF and a minority of those with PV. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Ahmad Alhuraiji, Kiran Naqvi, Yang O. Huh, Coty Ho, Srdan Verstovsek, Prithviraj Bose Source Type: research

Our Experience in the Treatment of Adult Lymphoblastic Leukemia (including Adult T-Cell Leukemia/Lymphoma) with German Multicenter ALL (GMALL) Protocol
acute lymphoblastic leukemia, chemotherapy, minimal residual disease. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Smbat Daghbashyan, Zhenya Nargizyan Source Type: research

Efficacy and Safety of Defibrotide to Treat Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) After Primary Chemotherapy: A Post Hoc Analysis of Final Data From an Expanded-Access Protocol
VOD/SOS, which may be unpredictable and potentially life-threatening, is typically considered a complication of hematopoietic stem cell transplantation (HSCT); VOD/SOS with multi-organ dysfunction (MOD) post-HSCT may be associated with>80% mortality. Defibrotide is approved to treat hepatic VOD/SOS with renal or pulmonary dysfunction post-HSCT in the US, and to treat severe hepatic VOD/SOS post-HSCT in the EU. However, VOD/SOS also can occur after chemotherapy without HSCT. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Nancy Kernan, Joseph Antin, Yoav Messinger, Wei Liang, Robin Hume, William Tappe, Paul Richardson Source Type: research

Frontline Inotuzumab Ozogamicin with Low-intensity Chemotherapy (mini-hyper-CVD) in Older Patients with Acute Lymphoblastic Leukemia (ALL): Updated Results of a Phase I/II Trial
Older patients with ALL are often intolerant to intensive chemotherapy and have poor outcomes. We hypothesized that combination of low-intensity chemotherapy with anti-CD22 antibody-drug conjugate inotuzumab ozogamicin (InO) may improve outcomes in the frontline setting. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Abhishek Maiti, Hagop Kantarjian, Susan O'Brien, Farhad Ravandi, Nicholas Short, Deborah Thomas, Guillermo Garcia-Manero, Naval Daver, Gautam Borthakur, Nitin Jain, Marina Konopleva, Koji Sasaki, Naveen Pemmaraju, Yesid Alvarado, Jovitta Jacob, Rebecca Ga Source Type: research

Frontline Ofatumumab with Hyper-CVAD in CD20+ Acute Lymphoblastic Leukemia (ALL): Updated Results of a Phase II Trial
Chemoimmunotherapy with hyper-CVAD is an effective frontline regimen for ALL. Ofatumumab potently binds to CD20 with better in vitro activity than rituximab. We hypothesized that addition of ofatumumab (O) to hyper-CVAD may improve outcomes in CD20+ ALL. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Abhishek Maiti, Hagop Kantarjian, Farhad Ravandi, Deborah Thomas, Maria Khouri, Guillermo Garcia-Manero, Rebecca Garris, Jorge Cortes, Nicholas Short, Koji Sasaki, Ghayas Issa, Paul Koller, Heather Schroeder, Tapan Kadia, Srdan Verstovsek, Naval Daver, Ni Source Type: research

Hyper-CVAD Plus Ponatinib as Frontline Therapy in Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL): Updated Results of a Phase II Trial
Chemotherapy in combination with tyrosine kinase inhibitors (TKI) are effective in Ph+ ALL. Ponatinib is a third-generation TKI which potently inhibits the BCR-ABL tyrosine kinase. Single-agent ponatinib has high activity in patients with Ph+ ALL but has dose-dependent cardiovascular toxicity. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Abhishek Maiti, Hagop Kantarjian, Farhad Ravandi, Nicholas Short, Naval Daver, Naveen Pemmaraju, Deborah Thomas, Musa Yilmaz, Tapan Kadia, Koji Sasaki, Rebecca Garris, Guillermo Garcia-Manero, Courtney DiNardo, Marina Konopleva, Zeev Estrov, Nitin Jain, W Source Type: research

Expression of CD 123 in Acute Lymphoblastic Leukemia and its Prognostic Impact
CD123 expression on blast cells and its prognostic value in acute leukemia as acute lymphoid leukemia (ALL) is a matter under investigation. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Taghreed Kamal Eldin, Eman M. Nagiub Abdelsalam, Ghadeer Abdel Razak, Howaida Nafady, Mostafa F. Mohammed Saleh Source Type: research

Identifying Transcription Factors that Dictate Drug-Resistance in Acute Lymphoblastic Leukemia
Acute Lymphoblastic Leukemia (ALL) is the most common pediatric malignancy and although approximately 98% of children enter complete remission within 6 weeks of standard chemotherapy regimens, 20% of children will relapse and approximately half relapse with drug resistant ALL. Dexamethasone and prednisone are glucocorticoids used in the treatment of pediatric blood cancers for over 50 years. The efficacy of glucocorticoid receptor modulation is well established in ALL but the response remains heterogeneous and limited by emergence of drug resistance. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Ninad Walavalkar, Nancy Lee, Michael Guertin Source Type: research